U.S. Markets open in 2 hrs 23 mins
  • S&P Futures

    4,571.75
    -4.00 (-0.09%)
     
  • Dow Futures

    34,606.00
    -16.00 (-0.05%)
     
  • Nasdaq Futures

    15,980.50
    -8.00 (-0.05%)
     
  • Russell 2000 Futures

    2,203.30
    -1.90 (-0.09%)
     
  • Crude Oil

    68.26
    +1.76 (+2.65%)
     
  • Gold

    1,769.70
    +9.00 (+0.51%)
     
  • Silver

    22.32
    +0.00 (+0.02%)
     
  • EUR/USD

    1.1313
    +0.0008 (+0.0679%)
     
  • 10-Yr Bond

    1.4480
    0.0000 (0.00%)
     
  • Vix

    27.79
    -3.33 (-10.70%)
     
  • GBP/USD

    1.3261
    -0.0041 (-0.3077%)
     
  • USD/JPY

    113.3480
    +0.1390 (+0.1228%)
     
  • BTC-USD

    57,101.84
    +747.95 (+1.33%)
     
  • CMC Crypto 200

    1,460.55
    +21.66 (+1.51%)
     
  • FTSE 100

    7,147.39
    +18.18 (+0.26%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CVS Health (CVS) closed the most recent trading day at $84.48, moving -1.58% from the previous trading session. This change lagged the S&P 500's 0.34% gain on the day.

Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had gained 0.39% over the past month. This has outpaced the Retail-Wholesale sector's loss of 1.38% and the S&P 500's loss of 0.12% in that time.

Wall Street will be looking for positivity from CVS as it approaches its next earnings report date. This is expected to be November 3, 2021. On that day, CVS is projected to report earnings of $1.78 per share, which would represent year-over-year growth of 7.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $70.23 billion, up 4.74% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $7.77 per share and revenue of $282.99 billion, which would represent changes of +3.6% and +5.32%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for CVS. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.8% lower. CVS currently has a Zacks Rank of #3 (Hold).

In terms of valuation, CVS is currently trading at a Forward P/E ratio of 11.04. Its industry sports an average Forward P/E of 9.7, so we one might conclude that CVS is trading at a premium comparatively.

Meanwhile, CVS's PEG ratio is currently 1.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Retail - Pharmacies and Drug Stores was holding an average PEG ratio of 1.61 at yesterday's closing price.

The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 243, which puts it in the bottom 5% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CVS Health Corporation (CVS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research